Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A
Jun Wang1,2, Fang Li1, Chunlong Ma1
1Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, 85721.
Abstract:
Influenza viruses are the causative agents for seasonal influenza, which results in thousands of deaths and millions of hospitalizations each year. Moreover, sporadic transmission of avian or swan influenza viruses to humans often leads to an influenza pandemic, as there is no preimmunity in the human body to fight against such novel strains. The metastable genome of the influenza viruses, coupled with the reassortment of different strains from a wide range of host origins, leads to the continuous evolution of the influenza virus diversity. Such characteristics of influenza viruses present a grand challenge in devising therapeutic strategies to combat influenza virus infection. This review summarizes recent progress in designing small molecule inhibitors that target the drug-resistant influenza A virus M2 proton channels and highlights the contribution of mechanistic studies of proton conductance to drug discovery. The lessons learned throughout the course of M2 drug discovery might provide insights for designing inhibitors that target other therapeutically important ion channels.
Insights
This review explores small molecule inhibitors targeting drug-resistant influenza A virus M2 proton channels. Mechanistic studies of proton conductance aid in discovering new influenza therapies and insights for other ion channel targets.
Area of Science:
- Virology
- Drug Discovery
- Structural Biology
Background:
- Influenza viruses cause seasonal epidemics and pandemics, posing significant global health threats.
- The continuous evolution of influenza virus diversity presents challenges for developing effective antiviral strategies.
- Drug-resistant strains, particularly influenza A, necessitate the development of novel therapeutic approaches.
Purpose of the Study:
- To review recent advancements in designing small molecule inhibitors against drug-resistant influenza A virus M2 proton channels.
- To highlight the role of mechanistic studies of proton conductance in guiding drug discovery efforts.
- To provide insights from M2 channel inhibitor development for targeting other ion channels.
Main Methods:
- Literature review of studies on small molecule inhibitors targeting influenza A virus M2 proton channels.
- Analysis of research focusing on the mechanism of proton conductance through the M2 channel.
- Synthesis of findings to inform future drug design strategies.
Main Results:
- Progress has been made in identifying and designing small molecule inhibitors for influenza A virus M2 proton channels.
- Mechanistic insights into proton conductance have proven valuable for structure-based drug design.
- The M2 channel serves as a validated target for antiviral drug development.
Conclusions:
- Small molecule inhibitors targeting the influenza A virus M2 proton channel are a promising therapeutic avenue.
- Understanding ion channel mechanisms is crucial for effective drug discovery.
- Lessons learned from M2 channel inhibitor development can be extrapolated to other therapeutically relevant ion channels.
More Related Videos
22:10Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
09:07Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
Related Concept Videos
01:27Influenza
01:30Inhibitors of Viral Protein Synthesis
02:28Leaky Scanning